Monitoring of vancomycin serum levels for the treatment of staphylococcal infections
Authors:
- 1 January 2006
- journal article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 12 (1) , 92-95
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Impact of High-InoculumStaphylococcus aureuson the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2004
- Vancomycin-resistant Staphylococcus aureus: no apocalypse nowClinical Microbiology and Infection, 2003
- Mississippi Mud No More: Cost‐Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent NephrotoxicityPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaireJournal of Antimicrobial Chemotherapy, 2002
- Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistanceThe Lancet Infectious Diseases, 2001
- Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized StudyAntimicrobial Agents and Chemotherapy, 2001
- Vancomycin Use in a Hospital With Vancomycin RestrictionInfection Control & Hospital Epidemiology, 1999
- Editorial: Monitoring Serum Vancomycin Levels: Climbing the Mountain Because It Is There?Clinical Infectious Diseases, 1994
- Nephrotoxicity of vancomycin, alone and with an aminoglycosideJournal of Antimicrobial Chemotherapy, 1990
- Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981Antimicrobial Agents and Chemotherapy, 1983